Skip to main content

Table 1 Baseline characteristics and mortality of cohort

From: Impact of coal mine dust exposure and cigarette smoking on lung disease in Appalachian coalminers

Variables

Mean±SD or %

Non-coal miners

(n=194)

Coal miners (n=362)

p-value

 

Never smokers

(n=46)

Ever-smokers

(n=148)

Never smokers

(n=124)

Ever-smokers

(n=238)

 

Demographics

     

Age (years)

64.2±3.7

64.3±10.9

69.6±10.7

72.5±8.1

<.01a

Male, %

26.1

35.8

99.2

99.2

<.01b

BMI, mg/kg2

32.1±9.3

27.8±6.1

29.2 ± 5.7

26.9±6.0

<.01c

Exposures

     

Coal, %

--

--

100

100

 

Coal-mine work duration (years)

--

--

30.9±9.6

29.1±10.1

.15

Underground work, %

--

--

37.9

26.8

<.01b

Silica, %

8.7

7.4

20.9

19.7

<.01b

Asbestos, %

2.2

5.4

11.3

13.4

.02

Smoking behavior

     

Current smoker, %

--

43.2

--

21.8

<.01b

Former smoker, %

--

56.8

--

78.2

<.01b

Years since quitting smoking

--

16.4±15.6

--

25.0±15.7

<.01b

Cigarettes per day

--

18.4±6.8

--

21.8 ±10.0

<.01b

Duration of smoking (years)

--

32.0±12.2

--

30.3 ± 16.2

.26

Composite pack years

--

27.9±12.0

--

34.6±25.8

<.01b

Comorbidities, %

     

COPD

15.2

52.0

38.7

70.2

<.01b

Hypertension

63.0

68.2

65.3

70.6

.65

Hyperlipidemia

47.8

59.5

55.6

64.7

.11

CVA

4.3

10.1

10.5

8.8

.63

PAD

0

9.5

3.2

3.8

.01b

CHF

4.3

6.8

11.3

16.4

.01b

CAD

17.4

33.1

41.1

47.9

<.01b

Afib

8.7

10.8

15.3

22.7

<.01b

VTE

13.0

13.5

6.4

10.9

.28

Diabetes

30.4

27.0

30.6

28.6

.92

OSA

8.7

12.2

20.2

18.9

.10

CKD

8.7

6.8

7.3

11.3

.39

GERD

30.4

44.6

41.1

47.1

.19

Mood disorders

17.4

37.2

16.9

18.1

<.01b

Pain disorder

23.9

36.5

12.1

10.1

<.01b

Hypothyroidism

30.4

20.9

17.7

13.4

.02

Liver dysfunction

4.3

3.4

4.8

5.5

.82

Home O2 use

2.2

11.5

37.9

59.2

<.01b

Mortality

4.3

20.3

13.7

29.0

<.01b

  1. Afib Atrial fibrillation, CAD coronary artery disease, CHF congestive heart failure, CKD chronic kidney disease, COPD chronic obstructive pulmonary diseases, CVA cerebro-vascular accidents, GERD gastro-esophageal reflux disease, OSA obstructive sleep apnea, PAD peripheral arterial disease, VTE venous thrombo-embolism
  2. asignificant difference noted between groups 1&3, 1&4, 2&3, 2&4, and 3&4
  3. bSignificant p-value with adjusted α=<.016 as per Bonferroni correction
  4. csignificant difference noted between groups 1&2, 1&3, 1&4 and 3&4